NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for viral infections. He highlighted that NV-387 has shown exceptional efficacy in preclinical studies, including curing RSV infections in animal models.
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human metapneumovirus (hMPV). The company is advancing NV-387, a promising broad-spectrum antiviral candidate designed to target a wide range of rapidly mutating RNA viruses.
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already. This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.
NanoViricides sees NV-387 as a key defense against bird flu pandemic
NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential bird flu pandemic caused by the H5N1 Influenza A virus. In a statement, the company claims the virus would be unable to evade NV-387, even as it mutates.
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. "Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R.
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America
The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), a clinical-stage nano-biopharmaceutical company that develops and commercializes drugs designed to treat viral infections, raises alarm over the evolving threat of H5N1 bird flu, highlighting recent research that shows the virus is just one mutation away from effectively targeting human cells.
NanoViricides pushes NV-387 to Phase II trials
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has taken steps towards starting a Phase II trial of NV-387 for the treatment of MPox infection in Central Africa.
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (Click Here
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides prepares for Phase II trials for antiviral NV-387
NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as COVID-19, RSV, and influenza.
